PRESS RELEASE published on 11/14/2023 at 12:45, 2 years 2 months ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 3 months ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 3 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 5 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 2 years 6 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 2 years 6 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 2 years 7 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 2 years 8 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 2 years 8 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 2 years 9 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Published on 01/31/2026 at 03:15, 1 day 11 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 13 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 15 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 23 hours 1 minute ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 2 hours ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 12 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 16 hours ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 18 hours ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 18:40, 1 day 20 hours ago ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 17:45, 1 day 21 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 1 day 21 hours ago Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 2 days 6 hours ago Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés
